Two Drugmakers Ask FDA to Lift Monotherapy Restrictions for MDD

International Pharmaceutical Regulatory Monitor
A A
Janssen and Takeda called for more flexibility in the FDA’s draft guidance for sponsors of drugs that treat major depressive disorder (MDD).

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00